Discovery of a novel IKK-β inhibitor by ligand-based virtual screening techniques
Open Access
- 1 January 2011
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (1) , 577-583
Abstract
No abstract availableKeywords
Funding Information
- Austrian Federal Ministry for Science and Research (S10702-B03, S10704-B03, S10703-B03)
- Technologiestipendien Südostasien Doktorat (ACM-2007-00178, ACM-2008-00857, ACM-2009-01206)
- University of Innsbruck, Austria
This publication has 36 references indexed in Scilit:
- Morphinans and isoquinolines: Acetylcholinesterase inhibition, pharmacophore modeling, and interaction with opioid receptorsBioorganic & Medicinal Chemistry, 2010
- How To Optimize Shape-Based Virtual Screening: Choosing the Right Query and Including Chemical InformationJournal of Chemical Information and Modeling, 2009
- IκBα Kinase Inhibitor IKI-1 Conferred Tumor Necrosis Factor α Sensitivity to Pancreatic Cancer Cells and a Xenograft Tumor ModelCancer Research, 2008
- New regulators of NF-κB in inflammationNature Reviews Immunology, 2008
- Synthesis and structure–activity relationship of aminopyrimidine IKK2 inhibitorsBioorganic & Medicinal Chemistry Letters, 2008
- IκB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challengesTrends in Pharmacological Sciences, 2007
- Pharmacophore Modeling and in Silico Screening for New P450 19 (Aromatase) InhibitorsJournal of Chemical Information and Modeling, 2006
- A selective novel low‐molecular‐weight inhibitor of IκB kinase‐β (IKK‐β) prevents pulmonary inflammation and shows broad anti‐inflammatory activityBritish Journal of Pharmacology, 2005
- Attenuation of Murine Collagen-Induced Arthritis by a Novel, Potent, Selective Small Molecule Inhibitor of IκB Kinase 2, TPCA-1 (2-[(Aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), Occurs via Reduction of Proinflammatory Cytokines and Antigen-Induced T Cell ProliferationThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Anticancer agent CHS 828 suppresses nuclear factor‐κB activity in cancer cells through downregulation of IKK activityInternational Journal of Cancer, 2004